151 related articles for article (PubMed ID: 24986093)
1. Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 2C9*3, 2C9*13, and 2C9*16 in vitro.
Chen SZ; Pan PP; Shen LB; Xu SS; Dai DP; Geng PW; Cai J; Cai JP; Hu GX
Int J Clin Pharmacol Ther; 2014 Sep; 52(9):732-8. PubMed ID: 24986093
[TBL] [Abstract][Full Text] [Related]
2. Effect of glimepiride and glibenclamide on S-warfarin 7-hydroxylation by human liver microsomes, recombinant human CYP2C9.1 and CYP2C9.3.
Iwakawa S; Miyashita K; Hashimoto Y; Kuroda T
Biol Pharm Bull; 2006 Sep; 29(9):1983-5. PubMed ID: 16946524
[TBL] [Abstract][Full Text] [Related]
3. Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects.
Maekawa K; Harakawa N; Sugiyama E; Tohkin M; Kim SR; Kaniwa N; Katori N; Hasegawa R; Yasuda K; Kamide K; Miyata T; Saito Y; Sawada J
Drug Metab Dispos; 2009 Sep; 37(9):1895-903. PubMed ID: 19541829
[TBL] [Abstract][Full Text] [Related]
4. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes.
Suzuki K; Yanagawa T; Shibasaki T; Kaniwa N; Hasegawa R; Tohkin M
Diabetes Res Clin Pract; 2006 May; 72(2):148-54. PubMed ID: 16325295
[TBL] [Abstract][Full Text] [Related]
5. Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.
Shon JH; Yoon YR; Kim MJ; Kim KA; Lim YC; Liu KH; Shin DH; Lee CH; Cha IJ; Shin JG
Br J Clin Pharmacol; 2005 May; 59(5):552-63. PubMed ID: 15842554
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo drug-drug interaction of losartan and glimepiride in rats and its possible mechanism.
Chen SZ; Pan PP; Wang SH; Luo J; Hu GX; Xu SS; Zhang L; Yu YF
Pharmacology; 2015; 95(3-4):133-8. PubMed ID: 25823852
[TBL] [Abstract][Full Text] [Related]
7. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development.
He SM; Zhou ZW; Li XT; Zhou SF
Curr Med Chem; 2011; 18(5):667-713. PubMed ID: 21182487
[TBL] [Abstract][Full Text] [Related]
8. Disposition of a CYP2C9 phenotyping agent, losartan, is not influenced by the common 3435C > T variation of the drug transporter gene ABCB1 (MDR1).
Yasar U; Babaoglu MO; Bozkurt A
Basic Clin Pharmacol Toxicol; 2008 Aug; 103(2):176-9. PubMed ID: 18816302
[TBL] [Abstract][Full Text] [Related]
9. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
Niemi M; Cascorbi I; Timm R; Kroemer HK; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
[TBL] [Abstract][Full Text] [Related]
10. In vitro assessment of 36 CYP2C9 allelic isoforms found in the Chinese population on the metabolism of glimepiride.
Dai DP; Wang SH; Geng PW; Hu GX; Cai JP
Basic Clin Pharmacol Toxicol; 2014 Apr; 114(4):305-10. PubMed ID: 24118918
[TBL] [Abstract][Full Text] [Related]
11. CYP2C9 genetic variants and losartan oxidation in a Turkish population.
Babaoglu MO; Yasar U; Sandberg M; Eliasson E; Dahl ML; Kayaalp SO; Bozkurt A
Eur J Clin Pharmacol; 2004 Jul; 60(5):337-42. PubMed ID: 15197523
[TBL] [Abstract][Full Text] [Related]
12. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists.
Taavitsainen P; Kiukaanniemi K; Pelkonen O
Eur J Clin Pharmacol; 2000 May; 56(2):135-40. PubMed ID: 10877007
[TBL] [Abstract][Full Text] [Related]
13. Genotype-phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region.
Varshney E; Saha N; Tandon M; Shrivastava V; Ali S
Eur J Drug Metab Pharmacokinet; 2013 Dec; 38(4):275-82. PubMed ID: 23446815
[TBL] [Abstract][Full Text] [Related]
14. Role of CYP2C9 polymorphism in losartan oxidation.
Yasar U ; Tybring G; Hidestrand M; Oscarson M; Ingelman-Sundberg M; Dahl ML; Eliasson E
Drug Metab Dispos; 2001 Jul; 29(7):1051-6. PubMed ID: 11408373
[TBL] [Abstract][Full Text] [Related]
15. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase.
Sandberg M; Yasar U; Strömberg P; Höög JO; Eliasson E
Br J Clin Pharmacol; 2002 Oct; 54(4):423-9. PubMed ID: 12392591
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients.
Gunes A; Coskun U; Boruban C; Gunel N; Babaoglu MO; Sencan O; Bozkurt A; Rane A; Hassan M; Zengil H; Yasar U
Basic Clin Pharmacol Toxicol; 2006 Feb; 98(2):197-200. PubMed ID: 16445595
[TBL] [Abstract][Full Text] [Related]
17. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
[TBL] [Abstract][Full Text] [Related]
18. Losartan hydroxylation phenotype in an Ecuadorian population: influence of CYP2C9 genetic polymorphism, habits and gender.
Dorado P; Beltrán LJ; Machín E; Peñas-Lledó EM; Terán E; Llerena A;
Pharmacogenomics; 2012 Nov; 13(15):1711-7. PubMed ID: 23171336
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH
Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
[TBL] [Abstract][Full Text] [Related]
20. Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients.
Yasar U; Sain-Guven G; Yardimci Y; Kilicarslan A; Babaoglu MO; Bozkurt A
Basic Clin Pharmacol Toxicol; 2011 Aug; 109(2):73-7. PubMed ID: 21332946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
